Entecavir

Several Bristol-Myers drugs had double-digit sales jumps. Those included Abilify, Orencia for rheumatoid arthritis, leukemia drug Sprycel and hepatitis B drug Baraclude. The company also launched its newest drug, Onglyza for diabetes,...

In this article: Bristol-Myers, Revenue, Abilify, Bipolar disorder, Baraclude, Sprycel, Plavix, Reyataz, Leukemia, and Orencia

...Sprycel, whose sales rose 41 percent to $107 million. Sales of Baraclude, used to fight infections with hepatitis B, surged 32 percent to $179 million, fueled by demand in China. Schizophrenia treatment Abilify, which does not cause...

In this article: Wyeth, Bristol-Myers, Revenue, Genentech, Sprycel, Bristol, Enbrel, and New York Stock Exchange

Entecavir Achieves Hepatitis B Suppression Through 2 Years: Presented At DDW ... Lamivudine, Entecavir Both Improved Prognosis in Hepatitis B-Related Acute-on ...

Entecavir Has Low Resistance Rates After 5-Year Treatment of Chronic Hepatitis B ... Lamivudine, Entecavir Both Improved Prognosis in Hepatitis B-Related Acute-on ...

Hopkins study identified risks for coinfected patients about taking entecavir ... find 2 units of umbilical cord blood reduce risk of leukemia recurrence ...

A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse ...

... receptor tyrosine kinase inhibitor for the treatment of acute myeloid leukemia. ... BARACLUDE(R) (Entecavir) Data Continue to Demonstrate Low Incidence of ...

UpToDate, electronic clinical resource tool for physicians and patients that provides information on Adult Primary ... leukemia ... Entecavir in the ...

Of these, 108 entecavir subjects and 95 lamivudine subjects completed questionnaires at week 48. ... While entecavir subjects achieved a clinically meaningful ...